Personalis Inc. Common Stock vs Stryker Corporation — how do they compare? Personalis Inc. Common Stock trades at $15.95 (market cap $1.70B), while Stryker Corporation trades at $285.51 (market cap $108.02B). The key difference: Stryker Corporation is far larger — about 63.5× Personalis Inc. Common Stock's market cap, and Stryker Corporation pays a 1.25% dividend while Personalis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Personalis Inc. Common Stock for 0 Days and Stryker Corporation for 22 Days on average.
| PSNL | SYK | |
|---|---|---|
Market Cap | $1.70B | $108.02B |
Volume | 3,262,398 | 2,222,698 |
Sector | Health | Health |
52-Week High | $18.38 | $388.35 |
52-Week Low | $5.04 | $269.75 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $1.52B | $119.49B |
Dividend Yield | — | 1.25% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Stryker (SYK) trades at $282.63, showing minimal daily change. The stock exhibits neutral technical signals with mixed moving averages and oscillators. Fundamentally, the company maintains strong profitability with a 14.43% net income margin and 16.51% ROE. Recent Q2 2026 earnings beat expectations, though Q1 2026 was a miss. Analyst sentiment is strongly bullish with a $365.89 consensus price target, but recent news highlights legal investigations and a manufacturing issue disclosure that caused an 8.8% share drop in early September 2026.
The outlook for SYK is cautiously optimistic. Strong fundamentals and analyst support suggest upside potential, but near-term risks from legal scrutiny and operational challenges could pressure the stock. Investors should weigh robust financial health against headline volatility ahead of Q3 2026 earnings on October 29, 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →